Sivik Global Healthcare LLC grew its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 120.0% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 110,000 shares of the biopharmaceutical company’s stock after acquiring an additional 60,000 shares during the period. Alexion Pharmaceuticals comprises 4.9% of Sivik Global Healthcare LLC’s investment portfolio, making the stock its biggest position. Sivik Global Healthcare LLC’s holdings in Alexion Pharmaceuticals were worth $13,384,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in shares of Alexion Pharmaceuticals by 7.0% during the 2nd quarter. BlackRock Inc. now owns 19,926,265 shares of the biopharmaceutical company’s stock valued at $2,424,428,000 after acquiring an additional 1,298,185 shares during the period. Vanguard Group Inc. grew its position in shares of Alexion Pharmaceuticals by 3.1% during the 1st quarter. Vanguard Group Inc. now owns 14,467,456 shares of the biopharmaceutical company’s stock valued at $1,754,034,000 after acquiring an additional 433,293 shares during the period. State Street Corp grew its position in shares of Alexion Pharmaceuticals by 6.8% during the 1st quarter. State Street Corp now owns 11,298,685 shares of the biopharmaceutical company’s stock valued at $1,369,846,000 after acquiring an additional 718,756 shares during the period. Ameriprise Financial Inc. grew its position in shares of Alexion Pharmaceuticals by 0.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 6,175,296 shares of the biopharmaceutical company’s stock valued at $751,363,000 after acquiring an additional 25,724 shares during the period. Finally, Bank of New York Mellon Corp grew its position in shares of Alexion Pharmaceuticals by 2.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 3,349,821 shares of the biopharmaceutical company’s stock valued at $407,573,000 after acquiring an additional 64,800 shares during the period. 94.26% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Alexion Pharmaceuticals, Inc. (ALXN) Stake Lifted by Sivik Global Healthcare LLC” was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/09/17/alexion-pharmaceuticals-inc-alxn-stake-lifted-by-sivik-global-healthcare-llc.html.

Several research analysts recently commented on the stock. Jefferies Group LLC set a $120.00 price objective on shares of Alexion Pharmaceuticals and gave the stock a “hold” rating in a report on Thursday, June 8th. UBS AG reaffirmed a “buy” rating and issued a $140.00 price objective (down from $143.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, May 31st. Stifel Nicolaus reaffirmed a “buy” rating and issued a $157.00 price objective on shares of Alexion Pharmaceuticals in a report on Wednesday, May 24th. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $180.00 price objective (up from $170.00) on shares of Alexion Pharmaceuticals in a report on Wednesday. Finally, J P Morgan Chase & Co reaffirmed a “hold” rating on shares of Alexion Pharmaceuticals in a report on Wednesday, June 14th. Five investment analysts have rated the stock with a hold rating, twenty have assigned a buy rating and three have issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $157.13.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) traded up 1.44% during midday trading on Friday, reaching $146.69. 3,713,613 shares of the company’s stock were exchanged. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $149.34. The stock has a market cap of $32.74 billion, a PE ratio of 63.61 and a beta of 1.40. The stock’s 50 day moving average is $138.83 and its 200-day moving average is $124.75.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The business had revenue of $912.00 million for the quarter, compared to the consensus estimate of $846.15 million. During the same quarter in the prior year, the firm posted $1.13 earnings per share. The business’s revenue for the quarter was up 21.1% on a year-over-year basis. On average, equities analysts expect that Alexion Pharmaceuticals, Inc. will post $5.62 EPS for the current year.

In related news, Director Ann M. Veneman sold 700 shares of the firm’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $137.74, for a total value of $96,418.00. Following the transaction, the director now owns 6,315 shares of the company’s stock, valued at approximately $869,828.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Ann M. Veneman sold 835 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the transaction, the director now directly owns 5,480 shares in the company, valued at approximately $799,038.80. The disclosure for this sale can be found here. In the last three months, insiders sold 17,070 shares of company stock worth $2,416,869. Insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.